FGA146

Cat. No.:	HY-161245
Molecular Formula:	$C_{24}H_{31}N_5O_6$
Molecular Weight:	485.53
Target:	Virus Protease; Cathepsin
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	FGA146 is a dual, selective inhibitor for M^{pro} and human Cathepsin L, with K_is of 2.19 μM, 0.96 μM and 0.87 μM, for Mal-M^{pro}, pET21-M^{pro} and Cathepsin L, respectively. FGA146 reveals an antiviral activity against SARS-CoV-2[1].		
IC_{50} & Target	cathepsin L 0.87 μM (Ki)	pET21-M^{pro} 0.96 μM (Ki)	Mal-M^{pro} 2.19 μM (Ki)

In Vitro

FGA146 reveals antiviral activity against SARS-CoV-2 with EC_{50} of 0.9 μM with low cytotoxicity[1].

FGA146 (25-100 μM) binds covalently to M^{pro} and decreases its thermal stability[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	Huh-7-ACE2
Concentration:	0-100 μM
Incubation Time:	24 h
Result:	Exhibited a CC_{50} of over 100 μM.

REFERENCES

[1]. Medrano FJ, et al., Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2. Commun Chem. 2024 Jan 18;7(1):15.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA